AI Read 400,000 Reddit Posts on Ozempic and Found Symptoms Trials Never Recorded

An AI analysis of more than 400,000 Reddit posts from nearly 70,000 users has surfaced side effects of GLP-1 drugs that clinical trials did not prominently record — including menstrual irregularities, chills, hot flashes and fatigue.

Researchers at the University of Pennsylvania School of Engineering and Applied Science examined more than five years of posts about semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound). Published September 13, 2026 in Nature Health.

What they found

44% of users reported some side effect. Gastrointestinal problems were the most common, as expected. Fatigue was the second most frequent complaint.

Nearly 4% of users reporting side effects described reproductive symptoms — bleeding between periods, heavy bleeding, irregular cycles. The authors note that figure would be higher in a female-only sample, since it is drawn from a mixed population.

Body temperature changes also recurred: chills, feeling cold, hot flashes and fever-like symptoms.

What computational social listening does

The method uses large language models — GPT and Gemini — to read unstructured text and categorise it, with the Medical Dictionary for Regulatory Activities (MedDRA) used to translate informal descriptions into standardised medical terminology.

That translation step is the technical core. A patient writes that they have been “freezing all the time” or “my cycle went haywire”; MedDRA supplies the controlled vocabulary that turns thousands of such phrasings into countable categories.

Doing it by hand across 400,000 posts is not feasible, which is why the dataset existed unanalysed rather than unavailable.

Why unprompted reporting is the point

“Clinical trials generally identify the most dangerous side effects,” explained co-author Lyle Ungar, but they “can fail to find what symptoms patients are most concerned about.”

The distinction is structural rather than a criticism of trials. Adverse events in a trial are collected against a predefined list and by direct questioning, which captures what investigators thought to ask about and systematically under-captures what they did not.

A patient writing to strangers online is describing what actually bothers them, unprompted and without a clinician present. That produces a different sample of experience — weighted toward what is disruptive to daily life rather than toward what is medically dangerous.

The two are not the same, and both matter.

The validation built into the result

“Some of the side effects we found, like nausea, are well known, and that shows the method is picking up a real signal,” said senior author Sharath Chandra Guntuku.

That reasoning is worth making explicit, because it is how an unvalidated method earns credibility. If the analysis recovered only novel findings, there would be no way to distinguish discovery from noise. Recovering the known side-effect profile first demonstrates the pipeline detects real patterns — which makes the unexpected findings worth attention rather than dismissal.

A plausible mechanism, offered cautiously

Co-author Jena Shaw Tronieri of Penn’s Center for Weight and Eating Disorders pointed to the hypothalamus: “These drugs are thought to work by engaging part of the brain called the hypothalamus, which helps regulate a wide variety of hormones.”

The suggestion has anatomical logic. The hypothalamus controls appetite, and it also governs the hormonal axis driving the menstrual cycle and the circuitry regulating body temperature — which would connect three otherwise unrelated reported symptoms to one location.

Rapid weight loss independently disrupts menstrual cycles through changes in body fat and energy availability, so the observation does not require a direct drug effect. Distinguishing the two would take a study designed for it.

What it cannot show

“We can’t say that GLP-1s are actually causing these symptoms,” said first author Neil K. R. Sehgal, describing menstrual irregularities as “a signal worth investigating.”

The limitations are specific. Reddit users skew younger, male and US-based, so the population is not representative of who takes these drugs — and a 4% reproductive-symptom rate drawn substantially from men is not a rate that transfers to female patients.

There is also no comparison group. Menstrual irregularity, fatigue and feeling cold are common in the general population, and without an unexposed comparator there is no way to know whether these occur more often on the drug.

The researchers plan to expand beyond Reddit and English-language communities. Tronieri disclosed a Novo Nordisk grant and consulting fees; the study reported no outside funding.

Where this fits in drug safety monitoring

Regulators already run spontaneous reporting systems — databases collecting adverse events submitted voluntarily by patients and clinicians — and social listening addresses a specific weakness in them.

Spontaneous reporting captures only what someone bothered to formally report, which skews heavily toward events a clinician judged serious enough to document. A patient who finds they are inexplicably cold, or whose cycle became irregular, has no obvious route to file that and often no reason to think it worth filing.

Online discussion captures it because the barrier is nil and the audience is peers rather than authorities. That makes it a genuinely complementary data source rather than a substitute.

The corresponding weakness is that a forum has no denominator and no controls, so it can suggest what to look for and cannot measure how often it happens. The realistic role is hypothesis generation — flagging candidates that then require a designed study with a comparison group, which is precisely how the authors frame it.

General information, not medical advice. Do not stop or change a prescribed medication without speaking to your clinician.